1. Clinical Overview
A fixed-dose combination (FDC) of Ondansetron, a selective 5-HT3 receptor antagonist, and Ranitidine, a histamine H2-receptor antagonist. This combination provides synergistic antiemetic and gastroprotective effects by targeting both the chemoreceptor trigger zone (CTZ) and gastric acid secretion. It is primarily used for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery, while also preventing stress ulceration and acid reflux. The FDC is widely used in Indian clinical practice, especially in oncology and surgical settings, though its regulatory status has been scrutinized by the Indian drug regulatory authority.
| Onset | Duration | Bioavailability |
|---|---|---|
| Ondansetron: Oral: 30-60 minutes; IV: 1-5 minutes. Ranitidine: Oral: 1-3 hours; IV: 15-30 minutes. | Ondansetron: Oral/IV: 8-12 hours. Ranitidine: Oral: Up to 12 hours; IV: 6-8 hours. | Ondansetron: Oral: Approximately 60% (subject to first-pass metabolism). Ranitidine: Oral: 50-60%. |
2. Mechanism of Action
The combination works via two distinct pathways. Ondansetron selectively blocks serotonin (5-HT3) receptors centrally in the chemoreceptor trigger zone (CTZ) of the area postrema and peripherally on vagal nerve terminals in the gastrointestinal tract, inhibiting the vomiting reflex. Ranitidine competitively inhibits histamine at H2 receptors of gastric parietal cells, leading to a marked reduction in basal and stimulated gastric acid secretion, volume, and hydrogen ion concentration. The combined action provides comprehensive management of nausea/vomiting while protecting the esophageal and gastric mucosa from acid-related damage, which is common during chemotherapy or post-surgery.
3. Indications & Uses
- Prevention & treatment of nausea and vomiting induced by moderately to highly emetogenic cancer chemotherapy.
- Prevention & treatment of postoperative nausea and vomiting (PONV).
- Management of nausea and vomiting associated with radiotherapy (total body irradiation or fractionated abdominal radiation).
4. Dosage & Administration
Adult Dosage: Typically, one tablet twice daily. Common strengths: Ondansetron 4 mg + Ranitidine 150 mg or Ondansetron 8 mg + Ranitidine 300 mg. For Chemotherapy: Ondansetron 8 mg + Ranitidine 150 mg twice daily, starting before chemotherapy. For PONV: Single dose preoperatively or postoperatively. Maximum daily dose of Ondansetron: 24 mg (as per most guidelines).
Administration: Tablets: Swallow whole with a glass of water, with or without food. To prevent chemotherapy-induced nausea/vomiting, take the first dose 30-60 minutes before the start of chemotherapy. For postoperative use, administer 1 hour before anesthesia. Do not crush or chew unless specified (e.g., dispersible).
5. Side Effects
Common side effects may include:
- Headache
- Constipation
- Diarrhea
- Dizziness
- Fatigue/Malaise
- Local injection site reactions (for IV form)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Apomorphine | Profound hypotension and loss of consciousness. | Contraindicated |
| Drugs prolonging QT interval (e.g., Class IA/III antiarrhythmics, macrolides, fluoroquinolones) | Additive risk of QT prolongation and cardiac arrhythmias. | Major |
| Phenytoin, Carbamazepine, Rifampicin | Induce CYP450 enzymes, reducing plasma concentration of ondansetron. | Moderate |
| CYP2D6 inhibitors (e.g., Fluoxetine, Quinidine) | May increase ondansetron concentration. | Moderate |
| Antacids, Sucralfate | May reduce absorption of ranitidine; administer at least 2 hours apart. | Moderate |
| Warfarin | Ranitidine may alter warfarin metabolism; monitor INR closely. | Moderate |
| Midazolam, Triazolam | Ranitidine may decrease hepatic metabolism, increasing their effect. | Moderate |
| Procainamide | Ranitidine may reduce renal clearance of procainamide, increasing toxicity risk. | Moderate |
| Dopamine agonists (e.g., Bromocriptine) | Ondansetron may antagonize the therapeutic effect. | Moderate |
7. Patient Counselling
- Do take the medication as prescribed, usually 30-60 minutes before chemotherapy or surgery.
- Do inform your doctor if you are pregnant, planning pregnancy, or breastfeeding.
- Do report any history of heart problems, liver disease, or kidney disease.
- Do maintain adequate fluid intake to prevent constipation.
- Don't crush or chew the tablets unless they are dispersible type.
- Don't take additional antacids within 2 hours of taking this medicine without consulting your doctor.
- Don't stop taking the medication abruptly if prescribed for a course.
8. Toxicology & Storage
Overdose: Ondansetron: Sudden transient blindness (IV), severe constipation, hypotension, dizziness. Ranitidine: Bradycardia, hypotension, vomiting, diarrhea, muscle cramps, confusion. Combined overdose may present with exaggerated anticholinergic-like effects (severe constipation, urinary retention) and cardiovascular instability.
Storage: Store at room temperature (15-30°C), protected from light and moisture. Keep in the original blister pack or container. Keep out of reach of children. Do not use after the expiry date printed on the pack. For injections: Store in carton to protect from light. Do not freeze.